Bis zu 90% sparen! Kostenloser Depotgebühren-Check
030-275 77 6400
DAX-0,42 % EUR/USD-0,22 % Gold+1,20 % Öl (Brent)-0,09 %

Xencor to Present at Upcoming Investor Conferences

Nachrichtenquelle: Business Wire (engl.)
01.08.2019, 22:01  |  103   |   |   

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will participate in three upcoming conferences:

  • Canaccord Genuity 39th Annual Growth Conference
    Date:
    Thursday, August 8, 2019
    Location: Boston, MA
  • BTIG Biotechnology Conference 2019
    Date:
    Monday, August 12, 2019
    Location: New York, NY
  • 2019 Wedbush PacGrow Healthcare Conference
    Date:
    Tuesday, August 13, 2019
    Location: New York, NY
    Presentation Time: 10:20 a.m. ET

A live webcast of 2019 Wedbush PacGrow Healthcare Conference will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. A replay of the event will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days following the presentation.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases. Currently, 14 candidates engineered with Xencor's XmAb technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Diesen Artikel teilen
Wertpapier
Xencor
Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.
NASDAQ


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel

Diskussionen zu den Werten

ZeitTitel
08.08.19